Replies to post #129836 on Biotech Values

[exwannabe]

Do you guys think that Sandoz would accept the entry of another generic just so Momenta could receive some type of reimbursement from Amphastar.

Of course not. But the back-off portion of the deals are more favorable to NVS than MNTA.

You want to look at a portion and not the totality, and in that you are wrong. If the totality of the deal is fair, then it does not matter if the royalties portion favors MNTA.